Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Brepocitinib yields improvements in cutaneous sarcoidosis

For patients with cutaneous sarcoidosis (CS), brepocitinib is associated with dose-dependent and clinically meaningful improvements, according to a study published online in JAMA Dermatology to coincide with the annual meeting of the American College of Rheumatology, held from Nov. 6 to 11 in Orlando, Florida.

Brepocitinib yields improvements in cutaneous sarcoidosis

A study published in JAMA Dermatology highlights the efficacy of brepocitinib in treating cutaneous sarcoidosis (CS), a historically neglected disease affecting adult patients. The Phase II, randomized, placebo-controlled trial led by Misha Rosenbach of the Perelman School of Medicine at the University of Pennsylvania enrolled 31 participants, randomly assigning them to receive brepocitinib 45 mg, brepocitinib 15 mg, or placebo once daily for 16 weeks.

Both brepocitinib doses demonstrated significant improvements in CS disease activity compared to placebo. The 45-mg group saw a 22.3 point increase in CSAMI-A scores, while the 15-mg group experienced a 22.2 point improvement, with placebo showing only a 0.7 point increase. These improvements were consistent across various end points, suggesting a dose-dependent effect of brepocitinib.

Brepocitinib 45 mg showed higher rates of complete or almost clear disease, CSAMI-A response, ≥10-point CSAMI-A reduction, and achieved a CSAMI-A score of 5 or less, compared to placebo. The clinical benefits extended to challenging patient cases, and the treatment was associated with significant improvements in skin-related quality of life.

Rosenbach emphasized the importance of this research, stating that it brings rigorous clinical evidence to the field, offering hope for more targeted and effective treatments for cutaneous sarcoidosis patients.

Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at medicalxpress.com →

More in Finance & Markets

More from Wednesday 18 November →